Identification of yeast DNA topoisomerase II mutants resistant to the antitumor drug doxorubicin: Implications for the mechanisms of doxorubicin action and cytotoxicity

Molecular Pharmacology

Volumn 52, Issue 4, 1997, Pages 658-666

  Patel, Sandhiya ^a   Sprung, Antje U ^a   Keller, Beatrice A ^a   Heaton, Victoria J ^a   Fisher, L Mark ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; FREE RADICAL;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOTOXICITY; DNA BINDING; DNA PROTEIN COMPLEX; DNA STRAND BREAKAGE; DRUG RESISTANCE; ENZYME BINDING; MITOCHONDRIAL RESPIRATION; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; YEAST;

EID: 0030861706     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.52.4.658     Document Type: Article

References (40)

1. Arcamone, F. Properties of antitumor anthracyclines and new developments in their application. Cancer Res. 45:5995-5999 (1985).
2. Carter, S. K. Adriamycin: a review. J. Natl. Cancer Inst. 55:1265-1274 (1975).
3. Gabbay, E. J., D. Grier, R. E. Fingerie, R. Reimer, R. Levy, S. W. Pearce, and W. D. Wilson. Interaction specificity of the anthracyclines with DNA. Biochemistry 15:2062-2070 (1976).
4. Crooke, S. T., V. H. Duvernnay, L. Galvan, and A. W. Prestayko. Structure-activity relationship of anthracyclines relative to effects on macromolecular synthesis. Mol. Pharmacol. 14:290-298 (1978).
5. Meriwether, W. D., and N. R. Bachur. Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia. Cancer Res. 32:1137-1142 (1972).
6. Ross, W. E., D. L. Glaubiger, and K. W. Kohn. Protein-associated DNA breaks in cells treated with adriamycin or ellipticine. Biochim. Biophys. Acta 519:23-30 (1978).
7. Lown, J. W., S. Sim, K. C. Majumdav, and T. Chaney. Strand scission of DNA by bound adriamycin and daunorubicin in the presence of reducing agents. Biochem. Biophys. Res. Commun. 76:705-710 (1977).
8. Tritton, T. R., and G. Lee. The anticancer agent adriamycin can be actively cytotoxic without entering cells. Science (Washington D. C.) 217:248-250 (1982).
9. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem. 65:635-692 (1996).
10. Rule, C., O. Ondrejickova, and K. Verner. Doxorubicin, daunorubicin, and mitoxantrone cytotoxicity in yeast. Mol. Pharmacol. 46:1234-1240 (1994).
11. Hixon, S. C., A. Ocak, J. E. Thomas, and J. P. Daugherty. Resistance to adriamycin toxicity among respiratory deficient mutants in yeast. Antimicrob. Agents Chemother. 17:443-449 (1980).
12. Tewey, K. M., T. C. Rowe, L. Yang, B. D. Halligan, and L. F. Liu. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science (Washington D. C.) 226:466-168 (1984).
13. Capranico, G., and F. Zunino. DNA topoisomerase-trapping antitumour drugs. Eur. J. Cancer 28A:2055-2060 (1992).
14. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58:351-357 (1989).
15. Deffie, A. M., J. K. Batra, and G. J. Goldenberg. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and resistant P388 leukemia cell lines. Cancer Res. 49:58-62 (1989).
16. Nitiss, J., and J. C. Wang. DNA topoisomerase-targeting anti-tumor drugs can be studied in yeast. Proc. Natl. Acad. Sci. USA 85:7501-7505 (1988).
17. Nitiss, J. L., Y-X. Liu, P. Harbury, M. Jannatipour, R. Wasserman, and J.C. Wang. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res. 52:4467-4472 (1992).
18. Nitiss, J. L., Y-X. Liu, and Y. Hsiung. A temperature-sensitive topoisomerase II allele confers temperature-dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors. Cancer Res. 53:89-93 (1993).
19. Nitiss, J. L., Y-X. Liu, and M. Jannatipour. Probing mechanisms of cell killing and resistance to antitopoisomerase II agents using yeast, in Molecular Biology of DNA Topoisomerases and its Application to Chemotherapy (T. Andoh, H. Ikeda, and M. Oguro, eds.). CRC Press, Boca Raton, FL, 287-297 (1993).
20. Berger, J. M., S. J. Gamblin, S. C. Harrison, and J. C. Wang. Structure and mechanism of DNA topoisomerase II. Nature (Lond.) 379:225-232 (1996).
21. Schiestl, R. H., and R. D. Gietz. High efficiency transformation of intact yeast cells using single-stranded nucleic acids as carrier. Curr. Genet. 16:339-346 (1989).
22. 2. Biochemistry 24:3199-3207 (1985).
23. Sikorski, R. S., and J. D. Boeke. In vitro mutagenesis and plasmid shuffling: from cloned gene to mutant yeast. Methods Enzymol. 194:302-318 (1991).
24. Liu, Y-X., Y. Hsiung, M. Jannatipour, Y. Yeh, and J. L. Nitiss. Yeast topoisomerase II mutants resistant to anti-topoisomerase II agents: identification and characterisation of new yeast topoisomerase II mutants selected for resistance to etoposide. Cancer Res. 54:2943-2951 (1994).
25. Hoffmann, C. S., and F. Winston. Ten-minute DNA preparation from yeast efficiently releases autonomous plasmids for transformation of Escherichia coli. Gene (Amst.) 57:262-272 (1987).
26. Dower, W. F., J. F. Miller, and C. W. Ragsdale. High efficiency transformation of E. coli by high voltage electroporation. Nucleic Acids Res. 16: 6127-6145 (1988).
27. Sanger, F., S. Nicklen, and A. R. Coulson. DNA sequencing with chainterminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463-5467 (1977).
28. Worland, S. T, and J. C. Wang. Inducible overexpression, purification, and active site mapping of DNA topoisomerase II from the yeast Saccharomyces cerevisiae. J. Biol. Chem. 264:4412-4416 (1989).
29. Wasserman, R. A., and J. C. Wang. Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine. Cancer Res. 54: 1795-1800 (1994).
30. Wasserman, R. A., C. A. Austin, L. M. Fisher, and J. C. Wang. Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: expression of a functional recombinant human topoisomerase IIα in yeast. Cancer Res. 53:3591-3596 (1993).
31. Austin, C. A., K. L. Marsh, R. A. Wasserman, E. Willmore, P. J. Sayer, J. C. Wang, and L. M. Fisher. Expression, domain structure and enzymatic properties of an active recombinant human DNA topoisomerase IIβ. J. Biol. Chem. 270:15739-15746 (1995).
32. Nitiss, J. L., and J. C. Wang. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol. Pharmacol. 50:1095-1102 (1996).
33. Vassetzky, Y. S., G. C. Alghisis, and S. M. Gasser. DNA topoisomerase II mutations and resistance to antitumour drugs. Bioessays 17:767-774 (1995).
34. Caron, P. R., and J. C. Wang. DNA topoisomerases as targets of therapeutics: a structural overview, in Molecular Biology of DNA Topoisomerases and its Application to Chemotherapy (T. Andoh, H. Ikeda, and M. Ogawa, eds.). CRC Press, Boca Raton, FL, 1-18 (1993).
35. Pastan, I., and M. Gottesman. Multiple drug resistance in cancer. N. Engl. J. Med. 316:1388-1393 (1987).
36. Cole, S. P., E. R. Channda, F. P. Dicke, J. H. Gerlach, and S. E. Mirski. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res. 51:3345-3352 (1991).
37. Feldhoff, P. W., S. E. Mirski, S. P. Cole, and D. M. Sullivan. Altered subcellular distribution of topoisomerase IIα in a drug-resistant human small cell lung cancer cell line. Cancer Res. 54:756-762 (1994).
38. Isabella, P., G. Capranico, M. Binaschi, S. Tinelli, and F. Zunino. Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells. Mol. Pharmacol. 37:11-16 (1989).
39. Withoff, S., W. N. Keith, A. J. Knol, J. C. Coutts, S. F. Hoare, N. H. Mulder, and E. G. E. de Vries. Selection of a subpopulation with fewer DNA topoisomerase lia gene copies in a doxorubicin-resistant cell line panel. Br. J. Cancer 74:502-507 (1996).
40. Meczes, E. L., K. L. Marsh, L. M. Fisher, M. P. Rogers, and C. A. Austin. Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2β construct allows the study of topoisomerase IIβ inhibitors in yeast. Cancer Chemother. Pharmacol. 39: 367-375 (1997).